dalteparin has been researched along with Hepatic Veno Occlusive Disease in 4 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dosage adjustments were made for patients developing renal failure." | 2.71 | Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. ( Couban, SH; Dorcas, VG; Forrest, DL; Pierce, R; Thompson, K, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xiang, H | 1 |
| Liu, C | 1 |
| Xiao, Z | 1 |
| Du, L | 1 |
| Wei, N | 1 |
| Liu, F | 1 |
| Song, Y | 1 |
| Gökce, M | 1 |
| Kuskonmaz, B | 1 |
| Cetin, M | 1 |
| Uckan Cetinkaya, D | 1 |
| Tuncer, M | 1 |
| Azık, F | 1 |
| Gökçebay, DG | 1 |
| Tavil, B | 1 |
| Işık, P | 1 |
| Tunç, B | 1 |
| Uçkan, D | 1 |
| Forrest, DL | 1 |
| Thompson, K | 1 |
| Dorcas, VG | 1 |
| Couban, SH | 1 |
| Pierce, R | 1 |
1 trial available for dalteparin and Hepatic Veno Occlusive Disease
| Article | Year |
|---|---|
Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study.
Topics: Adolescent; Adult; Dalteparin; Female; Hematopoietic Stem Cell Transplantation; Hemorrhage; Hepatic | 2003 |
3 other studies available for dalteparin and Hepatic Veno Occlusive Disease
| Article | Year |
|---|---|
Enoxaparin attenuates pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression.
Topics: Animals; Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Hepatic Veno-Occlusive Disease; | 2023 |
Coexisting or underlying risk factors of hepatic veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients receiving prophylaxis.
Topics: Administration, Oral; Adolescent; Age Factors; Amphotericin B; Anticoagulants; Antifungal Agents; Bu | 2013 |
Venous Thromboembolism after Allogeneic Pediatric Hematopoietic Stem Cell Transplantation: A Single-Center Study.
Topics: Activated Protein C Resistance; Adolescent; Allografts; Catheterization, Central Venous; Child; Chil | 2015 |